Clinical Trial Update: Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing fulvestrant to capecitabine as maintenance therapy after first-line chemotherapy in HR+/HER2- metastatic breast cancer is currently re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Fulvestrant (fulvestrant)

Snippet

Sponsor: Herui Yao | Conditions: Metastatic Breast Cancer | Phase 3 | Status: RECRUITING